Jenkins Suggests "Complete Response" Letter Transparency Could Prompt Better Drug Applications, Faster Reviews
Executive Summary
If FDA's transparency initiative results in the public release of "complete response" letters, Office of New Drugs Director John Jenkins sees a possible side benefit for the agency
You may also be interested in...
FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
Requirements to redact proprietary information from documents, make them accessible to the disabled, and other challenges would greatly tax FDA staff, FDA's Janet Woodcock says.
Who Will Lead FDA In The Future? Succession Plan Is Not Enough, GAO Says
In its latest report card on FDA, the Government Accountability Office examines the agency's management of such challenges as recruiting and retaining its workforce and communicating with the public
Who Will Lead FDA In The Future? Succession Plan Is Not Enough, GAO Says
In its latest report card on FDA, the Government Accountability Office examines the agency's management of such challenges as recruiting and retaining its workforce and communicating with the public